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Abstract
Recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF) are 
serious problems in IVF and ICSI cycles. Different factors are showed to be respon-
sible for these clinical challenges – such as paternal, maternal, embryonic, immuno-
logical, infectious, hormonal, and others. In this chapter we have tried to review the 
available data on reasons for the RIF, and systematize them into: 1) uterine factors; 
2) embryo factors; 3) immunological factors; 4) other factors. Interplay between 
all these factors play a role in RIF, and further investigations are needed to elucidate 
their significance and interactions – in order to elaborate more definite suggestions 
or guidelines for the clinicians dealing with artificial reproductive techniques and 
facing RPL and RIF.
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1. Introduction
1978 was the year when the first IVF baby Louise Brown was born. From that 
time reproductive technology progress grew exponentially as well as the experience 
in current field. In the next years after Louise Brown birth initial implantation rates 
were < 5% per embryo [1]. As ART technology progressed, many clinics replaced 
cleavage-stage embryos to blastocyst-stage embryos, and switched from multiple 
embryo transfers to double- or single-embryo transfers. Each of those achievements 
led to the point where modern reproductology stands.
Despite the accumulated experience and knowledge, there are many medical 
questions that need to be answered, because recurrent pregnancy loss (RPL) and 
recurrent implantation failure (RIF) still exist.
RPL is a disorder defined by the American Society for Reproductive Medicine 
(ASRM) as the loss of two or more consecutive clinical pregnancies until 20 weeks 
of gestation [2]. It is known that around 5% of all women are experiencing two 
consecutive pregnancy losses, 75% of which are implantation failures [3]. In the 
case of RIF, because of rapidly changing field of ART there has been always a lack of 
consensus on the definition of RIF, and up till today the definition of RIF is still not 
unanimous.
One of the first attempts to define RIF was done by Coulam twenty years ago. 
He defined RIF as a failure to achieve pregnancy with more than 12 embryos 
transferred in several procedures [4]. During the consecutive 20 years, more and 
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criteria have been added. A parameter of the blastocyst in the definition of RIF was 
introduced in 2007: it has been stated that for RIF to be diagnosed, in the patients 
history there should be the transfer of ≥8 of the 8-cell embryos, the transfer or ≥ 5 
blastocysts without achieving the pregnancy [5]. After that the researchers started 
to specify that good-quality embryos is also a significant factor that should be 
taken into account [6]. Good-quality embryo was defined as having the correct 
number of cells corresponding to the day of its development and day-5 embryos 
(blastocysts) were graded according to expansion and quality of the inner cell 
mass and trophectoderm [7]. Coughlan with colleagues in 2014 proposed defini-
tion in which they also added the age of women [8]. About the same time, Lukasz 
with co-workers stated that RIF should be defined as the absence of implantation 
defined by a negative serum hCG 14 days after oocyte collection, after two consecu-
tive cycles of IVF, ICSI or frozen embryo transfer, where the cumulative number of 
transferred embryos was no less than four for cleavage-stage embryos and no less 
than two for blastocysts, with all embryos being of good quality and of appropriate 
developmental stage [9]. The PGD Consortium, a specialized group of European 
Society of Human Reproduction and Embryology, suggested one of the last defini-
tions of RIF: it is a failure to achieve pregnancy after ≥3 embryo transfers (ET) of 
high-quality embryos in women <40 years, or transfers of ≥10 embryos in total in 
multiple transfers. Presence or absence of pregnancy is diagnosed by an ultrasound 
examination after the 5th week [8, 10, 11]. Implantation failure can depend on 
different factors. Successful embryo implantation is an interactive process between 
the blastocyst and the uterus. Synchronized development of embryos with uterine 
differentiation to a receptive state is necessary to complete pregnancy. Implantation 
failure may occur even on early stages during the embryo attachment or migra-
tion. As a result, there will be no objective evidence of a pregnancy, i.e. negative 
urine or blood pregnancy tests (negative hCG) [12]. Another scenario - embryo 
can migrate through the luminal surface of the endometrium and start to produce 
hCG, which may be detected in the blood or urine. But even on this stage the 
process could be disrupted before the formation of an intrauterine gestational sac. 
In general, implantation failure is usually distinguished into two groups. The first 
group included women who never shown quantifiable signs of implantation, such 
as increased levels of hCG. The second group include women who have an evidence 
of implantation (detectable hCG production) but it did not proceed beyond the 
formation of a gestational sac visible on ultrasonography 2 weeks later [8]. From 
the clinical point of view, as defined by the ASRM, implantation is considered 
successful when there is ultrasonographic evidence of an intrauterine gestational 
sac or by histopathological examination [2]. With vast numbers of potential causes 
to consider, to diagnose an etiology of implantation failure is still a complex task for 
every reproductologist. Some researchers attempted to present summarized reasons 
of RIF. For example, Timeva et al. have divided RIF causes in three main groups:  
1) multifactorial RIF with the subgroups of maternal or paternal factors, hormonal 
or metabolic disorders, infections and thrombophilias; 2) endometrial RIF that is 
caused due to thin (≤6 mm) endometrium, with or without variations in vascular-
ity; 3) idiopathic RIF, which is unexplained failure to achieve pregnancy after 
transfer of good quality embryos, without any anatomical and histological changes 
in uterine cavity and endometrium, without any other disturbances in patient, 
patient-partner and embryos [13]. Some other authors, in turn, have distinguished 
etiologic groups such as decreased endometrial receptivity, defective embryonic 
development and also multifactorial effectors, including into the multifactorial 
group endometriosis, hydrosalpinges and suboptimal ovarian stimulation [6]. 
However, there are two main causes of implantation failure that are always present 
in the majority of all the classifications: uterine and embryo factors. Therefore, we 
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will shortly review these two, and will also add some data on the immunological 
and other factors of interest in the context of RIF.
2. Uterine factors
2.1 Endometrial receptivity
Endometrial environment plays a crucial role in embryo implantation and early 
placental development. There is a certain period of endometrial maturation during 
which the trophectoderm of the blastocyst can attach to the endometrial epithelial 
cells and subsequently proceed to invade the endometrial stroma, which is called 
endometrial receptivity [14]. This complex process provides the embryo with the 
opportunity to normally attach, implant and develop.
There is a short period of time during the menstrual cycle, when the endometrial 
receptivity is optimal and embryo implantation is possible. This period is called “win-
dow of implantation” (WOI). Studies with donor embryos in humans have shown that 
this receptive period starts at day 6 post ovulation and continues 4–5 days (or 3–6 days) 
within the secretory phase (day 20–24 of the menstrual cycle) in most healthy women 
[15, 16]. Endometrium is unique in its ability to block embryos from implanting, except 
during this narrow window of receptivity, where endometrium undergoes morphologi-
cal, cytoskeletal, biochemical, and genetic changes [17]. As shown in the mouse models 
(and is also true in the other species), WOI is regulated by ovarian steroid hormones. 
In the receptive endometrium, crucial hormones are progesterone and 17β-estradiol 
[18, 19]. In certain pathologic conditions, this window is narrowed or shifted, which 
disrupts normal implantation, leading to infertility or pregnancy loss [15, 16].
2.2 Human endometrium transcriptomics
The transcriptome reflects the genes that are actively expressed at any given 
time within a specific cell population or tissue [20]. Human endometrial receptivity 
transcriptome is a rather complex issue because the quantity of crucial genes that 
plays a main role in receptivity is still a debatable question. Despite so many publi-
cations that revealed hundreds of simultaneously up- and down-regulated genes, 
the number of selected genes usually differs from one publication to another.
The early search using mouse models started with a few identified genes of 
receptivity, such as leukemia inhibitory factor-LIF, Homeobox protein X3, genes 
of embryo response- Cyclooxygenase 2-COX 2; and decidualization -Interleukin 11 
Receptor-IL-11R [20]. In 2003 from comparing the gene expression pattern of 375 
human cytokines, chemokines, and related factors in receptive and prereceptive 
human endometrium identified IGF-1 (insulin-like growth factor-binding protein) 
as a new endometrial receptivity gene [21]. Furthermore, Zhang et al. proposed 148 
receptivity biomarkers [22]. Tapia et al. suggested a list of 61 receptivity biomarkers 
[23]. Bhagwat et al. found 179 genes that have the potential to be called Receptivity 
Associated Genes [24]. In an enrichment analysis used to identify a meta-signature 
of highly presumed biomarkers of endometrial receptivity, a statistically significant 
meta-signature of 52 up-regulated and five down-regulated genes was identified 
[25]. The highest scores in receptive-phase endometrium reserved 5 up-regulated 
transcripts - GADD45A, SPP1, PAEP, GPX3 and MAOA. The five down-regulated 
transcripts receptivity-associated genes were SFRP4, EDN3, OLFM1, CRABP2 and 
MMP7 [22–24, 26, 27]. Interestingly, commercial Endometrial receptivity array 
(ERA test) by Igenomix [28, 29] shares 47 genes in common with the identified 57 
putative receptivity biomarkers.
Infertility and Assisted Reproduction
4
As the potential biomarkers for endometrial receptivity, many other molecules 
have been also studied - like mucin (MUC-1), trophinin, L-selectin, Wingless 
(Wnt) family members, etc. [30].
2.3 Endometrial receptivity Array
Endometrial receptivity array was developed and patented in 2009. The group 
of Garrido Gomez from Igenomix have developed a clinical algorithm with a 
computational predictor which test results are based on the expression analysis of 
248 genes [29]. Expression profiling is accomplished by assaying mRNA levels with 
microarrays or next-generation sequencing technologies (RNA-seq), that allowed 
identification of the transcriptomic signature of the window of implantation [31]. 
The idea is to detect a specific point in time of endometrial cycle in which the 
WOI starts, allowing physicians to perform personalized embryo transfer (pET). 
The accuracy and consistency of the ERA test had been demonstrated in several 
trials, that showed that the ERA test is a reliable and reproducible method for 
determination of the exact time of the WOI that can be used with better results in 
comparison to histological dating of endometrial receptivity [32]. A pilot study was 
conducted by Igenomix of 17 RIF patients, who underwent oocyte donation and 
routine embryo transfer (ET) but were then treated with pET after the personalized 
diagnosis of their WOI. This study demonstrated that embryo-endometrial syn-
chronization within an optimal time-frame increases the chances of success in an 
assisted reproductive treatment [33]. The same group showed that patients with at 
least three previous failed oocyte donation cycles, and IVF patients aged <40 years, 
with at least three failed IVF cycles with a receptive ERA diagnosis resulted in a 
62.8% pregnancy rate [20]. Other groups also showed increased probability of 
having successful implantation and pregnancy after performed pET in accordance 
to the ERA result. Results in the Indian population revealed an endometrial factor in 
27.5% of the RIF patients, which was significantly greater than 15% in the non-RIF 
group [17]. Increased percentages of non-receptive ERA test in women with RIF 
have been also demonstrated [17, 28, 34]. However, the data on the ability of the 
ERA test to improve the implantation chances in RIF patients are conflicting, with 
some studies showing no beneficial effect of the test [35, 36]. Also, some studies 
failed to demonstrated concordance between the ERA test and histological dating of 
the endometrial biopsies [37].
2.4 Uterine microbiome
Normal microbiome in healthy women primarily consists of hydrogen peroxide-
producing Lactobacilli species [38]. During infancy the vaginal flora consists 
of aerobic and anaerobic bacterial populations, including Streptococcus and 
Staphylococcus, Prevotella and Enterobacteria species [39]. When puberty comes, 
the estrogen production causes glycogen to rise and pH to decrease with subsequent 
domination by Lactobacilli species. Microbiomes of all reproductive organs (vagina, 
cervix, Fallopian tubes, and ovaries) are significantly correlated [40]. It has been 
suggested that instead of a single most frequent microbiome, there are multiple core 
microbiomes: either dominated by variety of Lactobacillus species, or with a lower 
percentage of Lactobacilli and dominance of anaerobic bacteria [38].
Studies indicate that lower diversity in the microbiome show better outcomes 
[41–43]. It seems that gravid vaginal microbiome tends to be more stable and less 
diverse through all the period of pregnancy [44] with major change such as an 
increase in the dominance of four Lactobacillus spp. (L. crispatus, L. jensenii, L. 
gasseri, and L. vaginalis) and a decrease in the amount of anaerobic species [45].
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Regarding the endometrial microbiome of women with RIF, Bacteroides and 
Proteobacteria seem to be the most represented [46]. Meta-analysis that was done 
in 2013 also proved that dysbiotic shifts are more frequent in subfertile population 
[47]. Also, a contamination from the transfer catheter tip by Enterobacteriaceae, 
Streptococcus, Staphylococcus, Escherichia coli and Gram-negative bacteria has a 
negative effect on implantation and pregnancy rates [48–52].
3. Embryo factors
3.1 Embryo quality
Blastocysts (day-5 embryos) are graded according to expansion and quality of 
the inner cell mass and trophectoderm. Other criteria include blastomeres of equal 
size and regular in distribution, distribution of cytoplasm without granularity and 
less than 10% fragmentation [7]. Good-quality embryo needs to have the correct 
number of cells corresponding to the day of its development. To make this state-
ment and describe all the pathological elements in development, at least 4 decades 
of research was needed to achieve the modern stage of embryo evaluation such as 
time-lapse imaging.
At early stages a morphological evaluation of the embryo was the only criteria 
for estimating developmental potential of embryo and predicting the probability 
of achieving pregnancy [53]. The history behind the science of current time-lapse 
embryo imaging goes back to 1997 when Payne et al. documented the use of time-
lapse video cinematography in order to observe the initial events in 38 normally 
fertilized human oocytes and compare these events with the day 3 embryo develop-
ment [54]. After ten years based on Payne et al. work, Mio and Maeda extended the 
analysis period to blastocyst stage and obtained 286 images of human oocytes and 
embryos [55]. At the same year, Lemmen and colleagues analyzed the events that 
occur during the first day of the development after fertilization of 102 oocytes by 
using a microscope with an enclosed camera system [56]. They were the first group 
that paid attention to embryo kinetic properties, by establishing a link between the 
early disappearance of pronuclei after fertilization, early first cleavage, and many 
blastomeres on day 2 of the development. After some period of time many authors 
started suggesting that kinetic properties need to be added to the morphological 
evaluation, like timing of embryonic cell divisions [57, 58].
At first the main focus was on time of first embryonic division or early cell 
division after which embryo becomes 2-cell organism. Correlation between preg-
nancy rate and time of early cell division was first studied by Edwards group [59]. 
They concluded that the transfer of embryos that cleaved 24–26 h after fertilization 
results in higher implantation and pregnancy rates compared to embryos with 
delayed division. Later many other publications showed that to fast or to slow 
cleavage has a negative impact on embryo development [60–62].
Modern time-lapse observation systems are developed for more optimized and 
accurate selection of viable embryos that includes morphological grading with 
the possibility to register kinetic parameters [60]. Time-lapse imaging has its own 
benefits, like low light exposure in relation to traditional morphology observation 
methods [63] and possibility of observing embryo inside incubator without moving 
it, which provides stable and uninterrupted conditions that could be beneficial for 
the final result [64].
Several statistical models were created to predict parameters like blastocyst stage 
development and quality. Morphokinetic algorithms that could predict successful 
implantation, biochemical or clinical pregnancy were described [60, 65, 66].
Infertility and Assisted Reproduction
6
3.2 Embryo aneuploidy
Throughout the life a human body and their cells are affected by many nega-
tive life-style and external environment factors. Adding the aging and cellular 
senescence, it results in errors in chromosome segregation during meiosis I and II 
[67]. Due to the aging of the oocytes, these errors lead to increase of embryos with 
abnormal chromosome number. The reasons behind these chromosome segregation 
errors are due to many factors, like incorrect formation of bivalents, derogation of 
cohesins, sister kinetochores separation by large distances and incorrect attachment 
of spindle microtubules to kinetochores during meiosis. Despite the well-known 
fact of decreasing quality of oocytes with aging, many women in the modern age 
delay having their first child until later in their life [68].
One of the largest studies on the impact of age on the aneuploidy rates was 
performed in 2011. More than 20 000 oocytes were obtained from 2830 patients 
with an average age of 38.8 years, and their polar bodies were examined using 
FISH method. A study detected 20% of aneuploidies in women at the age of 35 that 
increased to the nearly 60% aneuploidy oocytes in women over 43 years of age. Of 
all the tested oocytes, almost half of them (46.8%) were aneuploid [69].
Detection and management of embryo anomalies that occur due to the age, 
poor quality oocytes or sperm abnormalities may be accomplished by performing 
preimplantation genetic testing (PGT) that allows to pick up and transfer blasto-
cysts with normal genetic constitution.
The history of PGT goes back to 1989 when Handyside performed first pre-
implantation genetic diagnostic (PGD) cases detecting a Y chromosome-specific 
region with PCR in case of X-linked adrenoleukodystrophy and X-linked mental 
retardation [70]. Defining embryo gender can complement to genetic testing of 
monogenic disorders linked to the sex chromosomes.
With time PGT underwent significant methodological changes, starting from 
the polar body testing and blastomere analysis to adapting trophectoderm biopsy 
with subsequent blastocyst freezing [71]. In early days the blastomeres were ana-
lyzed using FISH method for chromosomes X, Y, 18, 13, and 21 [72]. The analysis of 
more than a single cell has led to a more robust downstream molecular investigation 
[73]. Molecular genetic testing started as analysis of single loci by PCR method and 
grew to sophisticated single cell whole genome amplification [74]. Also, instead of 
PGT many groups have tried to develop algorithms to detect ploidy based on mor-
phokinetic properties. There were several attempts to create such algorithms using 
time-lapse monitoring. The idea was based on assumption, that embryos display 
different cleavage dynamics depending on their genetic material, but this have not 
been fully proved [75, 76].
PGT consists of two main tests: PGT-M and PGT-A. PGT-M is a pre-implantation 
genetic testing of embryos for monogenic (or single gene) diseases. PGT-M is used 
on as a part of IVF process in couples with hereditary genetic disorders.
PGT-A (preimplantation genetic testing for aneuploidy) is a procedure that 
allows determining the chromosomal status of IVF embryos by screening all 23 
pairs of human chromosomes including sex chromosomes. Many different methods 
are used, which includes array comparative genomic hybridization (aCGH), quanti-
tative PCR (qPCR), single nucleotide polymorphism array (SNP array) and next-
generation sequencing (high and low resolution) (NGS). The difference between 
those methods is in quantity of genomic amplification, ability to detect balanced 
or unbalanced translocations, partial aneuploidies, polyploidy, and mosaicism. For 
example, Array CGH, SNP array, and high resolution NGS utilize whole genome 
amplification of genomic DNA but at the same time can introduce an artifact. 
Quantitative PCR and low resolution NGS are not able to amplify the whole genome 
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and because of their low genomic coverage small deletions or duplications could not 
be detected [72].
In the PGT-A results embryos can be diagnosed three ways: as euploid with 
the normal number of chromosomes; as aneuploid with abnormal number of 
chromosomes, or mosaic - where 2 different cell lines are present within the same 
embryo (often one euploid cell line and one aneuploid cell line). Regarding mosaic 
embryos, it has been shown that mosaicism rates decrease with extended embryo 
culture. This could happen due to embryos ability to self-correct or because euploid 
cell lines predominate at later developmental stages [77].
However, the data on the ability of the PGT-A to improve the implantation and 
live birth rates in RIF patients is also still a controversial issue [36, 78–80].
4. Immunologic factors
4.1 Lymphocytes Th1/Th2 profile and Th17
T lymphocytes are types of immune cells that originate from bone marrow and 
mature in thymus cortex. One of those mature populations of lymphocytes are 
T-helpers, which express antigens CD4. CD4+ T cells are divided into two major 
types: T helper 1 (Th1) and T helper 2 (Th2) cells. Th1and Th2 are characterized 
by cytokines that they secrete and are important in cellular and humoral immunity 
function. Th1 in general tends to be proinflammatory and secrete such cytokines 
as interferon-γ, TNF-α and interleukins (ILs) 1, 2, 6, 12, 15 providing help to other 
T cells and macrophages. Th2 on the other hand, cancel out the Th1 subpopulation 
and serve as anti-inflammatory agents that secrete ILs 4, 5, 10 and provide help to B 
cells, in the production of antibodies [81, 82].
During pregnancy, the milieu of Th cells in normal circumstances shifts towards 
the prevalence of Th2 subpopulation. It happens due to rise of Progesterone, which 
inhibits the secretion of Th1 cytokines. In immunologic profiles the levels of IL-4 
and IL-10 goes up and levels of IL-2, TNF-α and interferon-γ goes down. When 
the child is born, he/she also has a Th2-dominant cytokine milieu, which quickly 
changes because of the microbial colonization [83]. If the milieu reverses towards 
the Th1 cell dominance, it could impact pregnancy by causing cytokine-triggered 
abortion due to thrombotic/inflammatory processes in maternal uteroplacental 
blood vessels.
It has been demonstrated on mice that injection of Th1 cytokines, i.e., TNF-a 
or IFN-gamma mediates abortion, while the administration of TNF-a antagonists 
reduces the fetal loss [84]. However, Th1 prevalence in the peripheral blood during 
peri-implantation period is normal in healthy women, also, there is no correlation 
between cytokine expression and serum hormone levels, which makes screening 
tests difficult to use in predicting imbalance in future pregnancies [85, 86].
Liang et al. compared the ratios of pro- and anti-inflammatory cytokines 
IFN-c/IL-4, IFN-c/IL-10, IFN-c/TGF-b1, TNF-a/TGF- b1 in the RIF patients and 
women with successful pregnancies. They discovered the shift towards pro-
inflammation in RIF group [87]. Another group also indicated that without any 
difference in gestational age, the pro-inflammatory cytokine levels such as TNFα, 
IFNγ, are significantly higher in euploid miscarriages, than in healthy pregnant 
women at 10–14 weeks of pregnancy [88].
As the role of Th1/Th2 population gain more and more evidence of their 
relevance in fertility, the role of third population of cells like Th17 also gained 
attention. Th17 cells are types of T-helper lymphocytes that are characterized 
by pro-inflammatory cytokine IL-17 production. Signals such as transforming 
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growth factor beta (TGF-β), interleukin 6 (IL-6), interleukin 21 (IL-21) and 
interleukin 23 (IL-23) cause the Th17 formation in mice and humans while at 
the same time these signals inhibit regulatory T cell differentiation [89, 90]. 
IL-17 is a cytokine which promotes the expression of various mediators of 
inflammation while playing an important role in maintaining mucosal surfaces 
pathogen free. The loss of Th17 cell populations at mucosal surfaces is related 
to chronic inflammation and microbial translocation. It has been demonstrated 
that the levels of Th17 cells in peripheral blood lymphocytes do not change in 
women with normal pregnancy [91] but proportion of Th17 cells in the periph-
eral blood and decidua significantly increases in unexplained recurrent sponta-
neous abortion patients [92, 93].
4.2 TNF-a
Overproduction of TNF-a could have toxic effect of pregnancy despite its 
necessity to assure endometrial receptivity. By analyzing cytokine profile of 210 
women undergoing IVF with the endometrial secretion analysis technique, higher 
TNF-a and IL-1b levels have been detected in patients with the previous history of 
implantation failure that achieved clinical pregnancy [94]. This could emphasize, 
that proinflammatory cytokines are also needed for successful transfer, pregnancy 
to occur.
4.3 Regulatory T cells
Regulatory T cells, formally known as suppressor T cells or Tregs express 
the CD4, FOXP3, and CD25 biomarkers and develop from the same lineage 
as T-helpers [95]. These cells are best known for their function to generally 
suppress Th1- and Th17-mediated immunity, or in other words - to suppress 
autoreactive and alloreactive immune responses, thereby preventing autoim-
mune diseases and allograft rejection [96]. These cells also modulate the 
immune system and downregulate induction and proliferation of effector T 
cells (CD8+). Tregs are involved in the regulation of local maternal tolerance 
towards the fetus, their concentration increases within 2 days of conception in 
normal human pregnancy [97]. Expression of IL-10 and TGF-b by Tregs and 
its suppression potential is significantly reduced in patients with unexplained 
recurrent spontaneous miscarriage in comparison to fertile patients [98]. Tregs 
also regulate the CD8(+) T cell differentiation by significantly reducing the 
expression of perforin and granzyme B in the decidua compared to peripheral 
blood EM CD8(+) T cells, which may also play a crucial role in establishing the 
maternal immune tolerance cells [99]. It has been demonstrated that patients 
with recurrent miscarriages and cellular immune imbalance could be treated 
with intravenous immunoglobulin G given it increases the of Th17 and Foxp3(+) 
Treg cell numbers [100].
4.4 Natural killers (NK) and uterine NK (uNK)
Parents wishing for a pregnancy are not tissue-matched, therefore, a mother’s 
immune system has to be suppressed. NK cells seem to play an important role in this 
process [101].
Natural killer cells, or NK cells, are a type of cytotoxic lymphocytes. In the 
uterus there are a special type of Natural Killers that consists of two main subsets: 
CD56 + CD16+ cells (10% of uNK) with dim phenotype, and CD56 + CD16-cells 
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(90% of uNK) with bright phenotype [102]. The bright type that should be domi-
nant cell subset, has low cytotoxic ability and are potent in secreting the cyto-
kines [101].
IL-15 and IL-18 are involved in the maturation of uNK. As the potential mark-
ers of uNK activity, levels of IL-15 and IL-18 are positively correlated with uNK 
levels in patients with implantation failure [103]. uNK cells increase in numbers 
from about 70% up to 83.2% of the uterine leukocytes during the mid- to late 
luteal phase, and first trimester of pregnancy [104, 105]. In some studies, it has 
been established that uterine NK play a role in decidual vascularization. This 
elevation of uNK CD56 cells density could contribute to increased angiogenesis in 
pre-implantation period leading to reduced uterine artery resistance to blood flow, 
endometrial oedema and as a result to implantation failure [106, 107]. Abnormal 
decidual vascularization and the increase in angiogenic factors contribute to the 
development of miscarriages and implantation failures.
4.5 Altered expression of associated molecules
4.5.1 Prostaglandins
Prostaglandins are group of physiologically active lipid compounds called 
eicosanoids. Prostaglandins are synthetized from Arachidonic acid by the action 
of cyclooxygenase (COX) isoenzymes [108]. Their function is to sustain homeo-
stasis, mediate pathogenic mechanisms by stimulating a reaction in one tissue 
(inflammatory response) and inhibiting the same reaction in another tissue. 
The type of the receptor to which the prostaglandins bind determines these 
reactions.
Decidual cells also secrete prostaglandins that latter interacts in complex 
reactions with other cytokines, growth factors and hormones like progesterone, 
prolactin, relaxin.
Achache et al. suggested that decreased prostaglandin synthesis might be a key 
factor in altered endometrial receptivity, therefore plays a role in implantation 
failure. Levels of cytosolic phospholipase A2 (cPLA2a) and COX-2 that was mea-
sured by PCR and Western blot tests were found to be decreased in patients with 
RIF in comparison to the fertile group. It was suggested that it might be detrimental 
to implantation only when both enzymes are missing. Interestingly, in response to 
the decreased function and presence of these enzymes, secretory phospholipase 
A2 (sPLA2-IIA) was overexpressed. This overexpression most likely is a form of 
compensation to maintain release of arachidonic acid [109].
Another data on RIF patients show that they express defective endometrial PG 
on the days 21–24 of the cycle. It has been estimated at both mRNA and protein 
level that already mentioned enzymes such as cyclooxygenase-2 (COX-2), secretory 
phospholipase A2 group (sPLA2-IIA, sPLA2-V, sPLA2-IB), and other molecules like 
glypican-1, PG-E synthase, PG-E receptors, and lysophosphatidic acid receptor 3 
(LPA3), play an important role in PG synthesis and are found in very low concen-
trations in 85% of RIF patients [109].
4.5.2 HOX-a and E-cadherin
Certain type of transcription factors, such as HOXA-10 and E-Cadherin, could 
also play the potential role in the implantation process. HOXA-10 and E-Cadherin 
are localized in the glandular epithelium cells of endometrium. Specifically, 
HOXA-10 in the nuclei of stroma cells and E-Cadherin the cytoplasm of glandular 
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epithelium cells. Regarding HOXA-10 and E-cadherin expression, positive cor-
relation was established between significantly reduced levels of HOXA-10 and 
E-cadherin expression in women with the history RIF, as compared with a control 
group [110].
4.5.3 Leukemia inhibitory factor (LIF)
LIF primarily was identified as macrophage differentiation inductor of the 
myeloid leukemia M1 cell line [111]. Later LIF started to be considered as the first 
cytokine that is shown to play critical role in mice blastocyst development and 
implantation [112]. The other functions of LIF included proliferation, differentia-
tion and cell survival [113]. Given the fact that LIFs mRNA is expressed during 
days 18–28 of the menstrual cycle in the endometrium of the fertile women, it also 
suggests it has a role in human implantation [114]. LIF expression is regulated by 
Progesterone. Treating women with the progesterone receptor antagonist imme-
diately after ovulation, it reduces immunoreactivity of LIF at the expected time of 
implantation [115].
Evidence for LIF role in human fertility was described several authors showing 
that low concentrations of LIF in the uterine flushing fluid at day 26 may be a good 
predictor of successful implantation, while at the same time endometrial explants 
from infertile women and women with recurrent miscarriages secrete less LIF than 
those from fertile women [116–119].
4.5.4 Apolipoprotein A-I
From the proteomic analysis of the endometrial biopsies, a new molecule was 
found that could be a potential predictor of the endometriosis and even of the RIF 
patients.
Apolipoprotein A-I (Apo A-I) was identified as an anti-implantation protein, 
that is secreted by differentiating endometrium. It seems that higher expression 
of Apo A-I can be found in ectopic secretory endometrium in patients with endo-
metriosis. This statement implies that dysregulation of certain molecule secretion 
might be a significant factor in pathogenesis of endometriosis and a crucial point 
for RIF [120]. But more date on this “fingerprint” is needed to apply it to the 
diagnostics.
4.6 Antiphospholipid antibodies (APL)
Antiphospholipid syndrome (APS) is an autoimmune condition that is associ-
ated with thrombosis and morbidity in pregnancy [121]. The pathogenic pathway 
by which whose conditions occur are not yet fully understood but it is known that 
mechanisms may be heterogeneous. The main Antiphospholipid Antibodies (aPLs) 
that is found in APS are lupus anticoagulant (LA), anticardiolipin antibodies 
(aCLs) and anti-β2glycoprotein I antibodies (aβ2GPI) [122].
APS is diagnosed if at least one of three antiphospholipid antibodies are detected 
on two or more occasions within a 12-weeks interval, and is associated with a 
clinical condition such as thrombosis or morbidity in pregnancy. Morbidity in 
pregnancy includes preterm delivery due to eclampsia, preeclampsia, unexplained 
stillbirths at≥10 weeks of gestation, or placental insufficiency, and three or more 
consecutive miscarriages [123]. Recurrent early miscarriage is one of antiphospho-
lipid syndrome (APS) obstetrical features with the incidence of aPLs in 15–20% of 
the patients with recurrent miscarriages [122]. However, the link between APS and 
RIF should be further investigated.
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5. Other factors
5.1 Body mass index (BMI)
Obesity is defined as BMI equal to or more than 30. According to the WHO, 
more than 1.9 billion adults of the world population are suffering from the extra 
body mass (BMI >25), and more than 650 million are obese [124].
A significantly lower ongoing pregnancy rate and implantation rate in obese 
women have been reported [125, 126]. The implantation rate, pregnancy and live 
birth rate are shown to be lower in obese women with the tendency to progressively 
go down with each unit of BMI (kilograms per square meter) [127]. It has been also 
found that higher BMI is associated with lower clinical pregnancy rates especially in 
women under age 35 using their own oocytes [128].
5.2 Ovarian response to stimulation
The goal of ovarian stimulation is the collection of multiple dominant follicles in an 
effort to compensate for the inefficiencies of embryology culture, embryo selection, 
thus improving chances for successful conception in IVF [129]. The definition of poor 
ovarian response (POR) should be understood as an essential inability of woman’s 
ovaries to properly react to the selected stimulation [130]. At least two of the following 
three features must be present for the POR to be diagnosed: 1) advanced maternal age 
(≥40 years), or any other risk factor for POR; 2) a previous POR (≤3 oocytes with a 
conventional stimulation protocol); 3) an abnormal ovarian reserve test (antral follicle 
count: 5–7 follicles, or Anti-Mullerian hormone 0.5–1.1 ng/ml) [131–133].
There are many risk factors that may cause poor ovarian response: short men-
strual cycle, single ovary, ovarian cystectomy, smoking, unexplained infertility, 
previous chemotherapy and/or radiotherapy treatment, family history of premature 
menopause, pelvic infection, etc. Further studies are needed to elucidate the role of 
these factors in RIF.
5.3 Male factor
Many studies have emphasized the role of sperm DNA integrity on the fertility 
of a couple, also reporting the relationship of the increased sperm DNA damage 
and pregnancy loss after IVF and ICSI [134]. However, some studies have failed to 
support a hypothesis that sperm DNA integrity is an important factor in RIF [135], 
therefore, also this important question needs to be further investigated.
6. Conclusion
We have described that recurrent implantation failure in IVF cycles depends 
on the interplay of many factors - female factors (different aspects of the uterine 
health), embryo factors (embryo quality and aneuploidy), possibly male factors 
(sperm DNA integrity), immunological factors, and probably many more. More 
investigations are needed before the clinicians can be clearly advised what diagnos-
tic and treatment approaches must be implemented in the cases of RIF.
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